Moteur de recherche d’entreprises européennes
Financement de l’UE (3 992 892 €) : Réseau de recherche sur les organoïdes pancréatiques du cancer Hor28/08/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Réseau de recherche sur les organoïdes pancréatiques du cancer
The PRECODE Network (PancREatic Cancer OrganoiDs rEsearch) central mission is to establish pancreatic organoid research firmly in the European Union, by training the next generation of creative and innovative researchers in pancreatic cancer. This will be done through a shared doctorate program of excellence that fulfils the three “I”: international, interdisciplinary and intersectorial. Organoids can be viewed as small micro-organs which can recapitulate the organization and the function thereof. As micro-organs organoids can be used to reduce animal experiments and help to reach 3R goals. Organoids from pancreatic cancer will help us to learn which drugs might help in the therapy of this terrible disease. They can be isolated from a variety of clinical sources with minimal material needed. This makes them a perfect tool for precision medicine. Sequencing, metabolomics and high throughput in vitro experiments to deduct the best possible drug combination fit hand in glove with this approach. Training of ESRs will be achieved by e-learning, workshops and secondments. They will earn to cultivate and manipulate organoids as well as cutting edge molecular biology techniques. Therefore our work group consists of 15 beneficiaries and 7 partner organization (including three patient advocate groups from Sweden, Italy and Germany) to develop those technologies and to train ESRs in their application. PRECODE will therefore connect the concepts of investigation, education and innovation establishing a capacitation for the ESRs that goes beyond the state of the art and that will allow them to improve their competences and their professional career at the same time that we advance towards innovation in the field of pancreatic cancer research.
| Astrazeneca UK Ltd. | 303 173 € |
| Cellphenomics GmbH | 252 788 € |
| Friedrich-Alexander-Universitaet Erlangen-Nuernberg | 252 788 € |
| Gdanski Uniwersytet Medyczny | 227 479 € |
| Karolinska Institutet | 281 983 € |
| Klinikum DER Technischen Universität München (TUM Klinikum) | 252 788 € |
| Mimetas B.V. | 265 620 € |
| Stichting Amsterdam UMC | 265 620 € |
| The Provost, Fellows Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | 274 684 € |
| Umea Universitet | 281 983 € |
| Universidad de Navarra | 250 905 € |
| Universita Degli Studi Di Verona | 261 500 € |
| Universitatsklinikum Erlangen | 252 788 € |
| Universiteit Leiden | 265 620 € |
| University of Glasgow | 303 173 € |
https://cordis.europa.eu/project/id/861196
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.